StockGuru Blog: Statsure Diagnostic Systems – HIV/AIDS Testing to Become the Norm

StatSure Diagnostic Systems, Inc. – SSUR HIV/AIDS Testing to Become the Norm Disease trackers estimate that 250,000 Americans are infected with HIV but do not know it. The yearly number of new infections has held steady over the last decade. It is not uncommon, specialists said, for people to carry the virus for ten years or longer and not be aware they are infected. Dr. Julie L. Gerberding, director of the US Centers for Disease Control and Prevention, said the guidelines are intended to identify infections sooner, get patients into treatment faster, and prevent further transmission of the virus, which is believed to infect 1 million Americans. “When people know they’re positive, the research has shown they take steps to protect others from infection,” Gerberding said. “People who don’t know it continue to transmit the virus.” AIDS specialists said the guidelines could alter the course of the epidemic in the United States. Healthcare economists said universal screening for HIV is at least as cost-effective as tests that detect diabetes, breast cancer, and other chronic conditions because if an HIV infection is caught early, medicines can give patients a long, productive life. “HIV testing is an excellent use of our healthcare dollar,” said A. David Paltiel, a health policy analyst at Yale University School of Medicine. SSUR Offers HIV/Aids Testing: SSUR SSUR offers HIV/AIDS testing. Serum and saliva tests are normally done in a hospital, clinic, or other professional environment and a blood test that is entirely self contained and very simple to use. In fact, depending upon local regulations from country to country, the blood test is simple enough to be done by almost anyone, almost anywhere, including not only a physician’s office, a clinic, hospital, or pharmacy, but including testing done on one’s self, in the privacy of one’s own home. All SDS rapid tests, StatSure and StatSimple, require no special handling, mixing, storage, electricity, refrigeration or specialized training (U.S. Patent #5,935,864), Sources: Center for Disease Control and Statsure Source: StatSure Diagnostic Systems, Inc. 1 Clarks Hill Rd. Framingham, MA 01702 Phone: 508-872-2625 Fax: 508-872-2728 http://www.statsurediagnostics.com View the StockGuru Profile for StatSure Diagnostic Systems, Inc.: http://www.stockguru.com/profiles/ssur/ About Statsure: SSUR develops rapid immunoassays for detecting antibodies to viruses and bacteria including HIV & H. pylori. It also makes specimen-collection devices (Saliva*Sampler and Omni-Swab) sold in the US; its Omni-SAL saliva-collection kit is sold in the UK. The Sero*Strip HIV test (approved by the World Health Organization), Hema*Strip HIV, and Saliva*Strip HIV tests detect HIV antibodies within minutes using patient serum, blood, or saliva. The serum and blood HIV tests are sold outside the US. Products are distributed through licensing agreements with other companies. Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4268. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $24,000 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Forward Looking Statement: To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.